SkinBioTherapeutics plc (AIM:SBTX)

London flag London · Delayed Price · Currency is GBP · Price in GBX
19.25
+0.50 (2.67%)
May 27, 2025, 4:35 PM GMT+1
92.50%
Market Cap 43.68M
Revenue (ttm) 2.68M
Net Income (ttm) -2.58M
Shares Out 232.98M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 523,171
Average Volume 796,361
Open 18.82
Previous Close 18.75
Day's Range 18.50 - 19.50
52-Week Range 8.32 - 27.50
Beta 0.78
RSI 38.41
Earnings Date Jun 24, 2025

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development. The company has an agreement with... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 15
Stock Exchange London Stock Exchange AIM
Ticker Symbol SBTX
Full Company Profile

Financial Performance

In 2024, SkinBioTherapeutics's revenue was 1.21 million, an increase of 815.26% compared to the previous year's 132,057. Losses were -2.88 million, 1.44% more than in 2023.

Financial Statements

News

There is no news available yet.